{"id":"NCT01424566","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer","officialTitle":"A Two-part, Placebo-controlled, Study of the Safety and Efficacy of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Have Inadequate Analgesia Even With Optimized Chronic Opioid Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-29","primaryCompletion":"2015-07-10","completion":"2015-12-28","firstPosted":"2011-08-29","resultsPosted":"2018-04-23","lastUpdate":"2023-04-12"},"enrollment":406,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain","Advanced Cancer"],"interventions":[{"type":"DRUG","name":"Nabiximols","otherNames":["Sativex®"]},{"type":"DRUG","name":"Placebo (GA-0034)","otherNames":[]}],"arms":[{"label":"Nabiximols","type":"EXPERIMENTAL"},{"label":"Placebo (GA-0034)","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study was to evaluate the efficacy of nabiximols (Sativex®), compared with placebo, when used as an adjunctive measure in relieving uncontrolled persistent chronic pain (not breakthrough pain) in participants with advanced cancer, who had inadequate analgesia even with optimized chronic opioid therapy.\n\nThis multi-center study was conducted in two parts. All participants enrolled into the trial received nabiximols during one of two parts of the study, but they did not know which part.\n\nEligible participants were not required to stop any of their current treatments or medications.","primaryOutcome":{"measure":"Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment","timeFrame":"Randomization Baseline, End of Treatment (Day 36 of the double-blind period)","effectByArm":[{"arm":"Double-blind Nabiximols","deltaMin":0.5,"sd":1.3},{"arm":"Double-blind Placebo (GA-0034)","deltaMin":0.5,"sd":1.6}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9173"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":65,"countries":["Australia","Bulgaria","Germany","Hungary","India","Israel","Italy","Lithuania","Poland","Romania","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["28785408"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":80,"n":404},"commonTop":["Somnolence","Dizziness","Nausea","Vomiting","Asthenia"]}}